Angiogenesis is one of the prime factors required for the formation of blood vessels and capillaries from pre-existing blood vessels. It plays a major role during embryonic development but is detrimental during the later stage as uncontrolled angiogenesis will lead to the formation of tumours and other disorders such as neurodegenerative diseases. Hence to combat this irregularity and maintain balance, a major receptor called VEGF needs to be targeted. Therefore many recent studies are based upon experiments using drug molecule from a plant source which has no side effects and effective in blocking the pro-angiogenic factors. In this context, our present study is based on investigating the antiangiogenic effect of Bergenin using the preliminary and widely used in-vivo model called CAM. Bergenin is a natural compound found in rhizomes ofBergenia species.It has various medicinal properties including anti-inflammatory, anti-oxidant,neuroprotective activity andmany more. The CAM Assay in our study is followed by a cell viability assay on macrophages which show Bergenin to be non-toxic. Also, at the highest concentration, Bergenin has shown good antiangiogenic activity by inhibiting the formation of blood vessels in the chorioallantoic membrane when compared with the standard drug molecule.The above findings indicate that the molecule Bergenin can be further used in high throughput screening of its antiangiogenic property and can be used as a valuable lead molecule in drug discovery and development against cancer and other neuroinflammatory diseases.